Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

13.04 -4.4

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

13.01

Max

13.35

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.4M -14M
EPS	-0.15
Werknemers	37
EBITDA	312K -12M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+141.78% upside

Dividenden
By Acuity
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-161M 1.2B
Vorige openingsprijs	17.44
Vorige sluitingsprijs	13.04

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 jul 2026, 23:56 UTC

Fox Corp shares are lower in after-market hours, with no specific news identified to explain the decline. The stock remains stable within its one-month trading range.

24 jul 2026, 23:56 UTC

Lumen Technologies Inc shares are higher in after-market trading, continuing fluctuations despite a broader trend of declines over the past month. No specific news identified.

24 jul 2026, 23:56 UTC

Correlated Moves

State Street Corp shares are lower in after-market trading, reflecting broader market dynamics amid turmoil in the bond markets and sector trends.

24 jul 2026, 23:56 UTC

Wingstop Inc. shares are higher in after-market trading, recovering from an earlier dip. The stock remains near the lower end of its one-month range.

24 jul 2026, 23:56 UTC

Cracker Barrel Old Country Store shares are lower in after-market hours. No specific news was identified to explain the decline amid broader market conditions.

24 jul 2026, 23:56 UTC

Carpenter Technology Corp shares are lower in after-market trading, reflecting broader market trends amid rising concerns in the bond markets.

24 jul 2026, 23:56 UTC

CMS Energy shares are higher in after-market trading following a slight pullback earlier in the session. The stock has advanced since Friday's close.

24 jul 2026, 23:56 UTC

DocuSign Inc shares are lower in after-market hours, reflecting a slight decline since Friday's close amid narrow trading fluctuations and no specific news.

24 jul 2026, 23:56 UTC

JD.Com shares were lower in after-market trading, despite briefly peaking shortly after market open. The stock remains near the upper end of its one-month range.

24 jul 2026, 23:56 UTC

Correlated Moves

Ares Capital Corp shares declined slightly in after-market trading, reflecting broader financial sector trends amid turmoil in bond markets and rising spreads.

24 jul 2026, 23:56 UTC

Correlated Moves

ON Semiconductor shares are higher in after-market trading, tracking MACOM's advance. The stock remains near the lower end of its one-month range.

24 jul 2026, 23:56 UTC

Aptiv PLC shares are trading higher in after-market hours, remaining near the lower end of their one-month trading range. No specific news was identified.

24 jul 2026, 23:56 UTC

The iShares MSCI South Korea ETF is trading lower in after-market hours, continuing a decline since Friday's close. No specific news was identified.

24 jul 2026, 23:52 UTC

S&P/Case-Shiller Home Price Index Set to Show 5.2% Increase Amid Mixed Economic Sentiment and Rising Inflation Concerns

24 jul 2026, 23:52 UTC

South Africa's Upcoming Balance of Trade Data Sparks Caution Amid First Trade Deficit and Global Supply Chain Tensions.

24 jul 2026, 23:51 UTC

UnitedHealth Group Inc shares are lower in after-market hours, continuing a decline since Friday's close amid broader market trends. No specific news was identified.

24 jul 2026, 23:51 UTC

Wendy's Co shares are higher in after-market hours, continuing an upward trend from earlier in the session, despite no specific news driving the move.

24 jul 2026, 23:51 UTC

Pilgrim's Pride Corp shares are higher in after-market trading, continuing gains from Friday's close and nearing the upper end of their one-month trading range.

24 jul 2026, 23:51 UTC

Axon Enterprise Inc shares are trading lower in after-market hours, reaching a session low amid broader turmoil in bond markets affecting credit investors.

24 jul 2026, 23:51 UTC

Clear Secure Inc shares are higher in after-market trading, recovering from an initial dip. The stock remains near the lower end of its one-month range.

24 jul 2026, 23:51 UTC

indie Semiconductor Inc. shares were roughly flat in after-market hours, following four consecutive daily declines amid ongoing market challenges.

24 jul 2026, 23:51 UTC

Howmet Aerospace Inc shares are higher in after-market trading, continuing a trend of five consecutive sessions of gains. No specific news was identified for the move.

24 jul 2026, 23:51 UTC

Trimble Inc shares are higher in after-market trading, showing resilience despite challenging macroeconomic conditions and no specific company news identified.

24 jul 2026, 23:51 UTC

Constellation Brands Inc shares are higher in after-market hours, reflecting modest gains since Friday's close despite broader bond market turmoil.

24 jul 2026, 23:51 UTC

East West Bancorp Inc shares are higher in after-market trading, reflecting notable strength since Friday's close, with no specific news identified.

24 jul 2026, 23:51 UTC

U.S. equity indices remain flat as investors weigh mixed earnings, geopolitical tensions, and a surprising drop in jobless claims amidst rising oil prices.

24 jul 2026, 23:51 UTC

Global equity markets show mixed performance as European indices rise on positive economic data, while Asian markets decline amid geopolitical tensions and rising oil prices.

24 jul 2026, 23:51 UTC

European equity indices rebound on strong PMI data, while Asian markets decline amid rising oil prices and geopolitical tensions.

24 jul 2026, 23:51 UTC

Asian equity markets decline amid rising oil prices and geopolitical tensions, while Germany's DAX rises; U.S. stocks remain flat as investors await key economic data.

24 jul 2026, 23:51 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, reflecting a notable decline since Friday's close, with no specific news identified.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

141.78% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD 141.78%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.